Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Dr Reddy's Laboratories - Q2FY21 First Cut - ICICI Securities

Posted On: 2020-10-28 09:23:05

(CMP - Rs. 5062, MCap - Rs. 84167 crore)

Dr Reddy's Laboratories' Q2FY21 revenues were better than I-direct estimates on all fronts on the back of strong growth in US, Europe and Indian markets and better than expected operational performance.

Q2FY21 Earnings Summary

- Revenues grew 2.0% YoY to Rs. 4911 crore (I-direct estimate: Rs. 4564 crore) mainly due to strong growth in US, Europe and Indian markets partially offset by high base effect in Q2FY20 (divestiture of certain proprietary product brands). The PSAI segment also posted a robust 19.7% YoY growth to Rs. 851 crore (I-Direct estimate: Rs. 817 crore). US revenues grew 28.5% YoY to Rs. 1833 crore (I-Direct estimate: Rs. 1736 crore) on the back of rupee depreciation and new product launches. Domestic revenues grew 21.5% YoY to Rs. 912 crore (I-direct estimate: Rs. 801 crore) due to Wockhardt integration and Covid related products. Europe revenues grew 35.8% YoY to Rs. 375 crore (I-Direct estimate: Rs. 346 crore) due to new launches and currency tailwinds. Russia & Other CIS revenues grew 3.4% YoY to Rs. 600 crore (I-Direct estimate: Rs. 493 crore). ROW sales grew 6.5% YoY to Rs. 264 crore (I-Direct estimate: Rs. 297 crore)

- EBITDA margins expanded 144 bps YoY to 23.5% (I-Direct estimate: 22.7%) due to lower other expenses partially offset by higher raw material and staff costs. Subsequently, EBITDA grew 8.7% YoY to Rs. 1156 crore against I-direct estimate of Rs. 1037 crore

- Net profit de-grew 30.3% YoY to Rs. 772 crore (I-direct estimate: Rs. 608 crore). Delta vis--vis EBITDA was mainly due to negative tax in Q2FY20

The management remains committed to working on cost rationalisation, especially on the SGN&A front and calibrating of R&D spend more towards Global Generics front & Biosimilars and lower towards proprietary products. Key growth drivers in the near term would be key launches across geographies besides continuing growth momentum in Global Generics especially in India and Russia.

We would be coming out with a detailed report post interaction with the management.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4949.8 as compared to the previous close of Rs. 5100.3. The total number of shares traded during the day was 151548 in over 12790 trades.

The stock hit an intraday high of Rs. 5148 and intraday low of 4921.5. The net turnover during the day was Rs. 768034167.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Auto Sector - Monthly Volume Round-up - Nov 20 - Reliance Securities

What do brokerages say on Burger King India Limited's IPO?

The Phoenix Mills - Potential fund infusion may usher in growth - ICICI Securities

Godrej Agrovet - Beneficiary of 60% increase in palm oil prices - ICICI Securities

Automobiles (wholesale) - Wholesale dispatches rise amidst modest retail trends - ICICI Securities

Oil & Gas - Sector Update - Dec 2020 - ICICI Direct

Phoenix Mills (Buy): Asset monetisation at favourable terms... - ICICI Direct

Aditya Makharia's views on November Auto Sales Number for November 2020 - HDFC Securities

Burger King India - IPO Review - ICICI Direct

Quant Pick - LIC Housing Finance - ICICI Direct

Tech Mahindra - Analyst Meet Update - ICICI Direct

Gladiator Stocks - Crompton Greaves Consumer Electricals - ICICI Direct

Derivatives Monthly Outlook - Nifty support at 12800 for ongoing momentum...

Quant Pick - Sun Pharmaceuticals - ICICI Direct

Monetary Policy - Expectation from YES Securities

Sector Update on Asset Management Companies - Subdued but improvement expected - HDFC Securities

Pre Monetary Policy View - Dec, 2020 - Lakshmi Iyer, President and CIO (Debt) & Head Products, Kotak Mutual Fund

Maintain REDUCE on Siemens - Smart recovery priced in - HDFC Securities

Banking Sector Credit Trends - Growth continues to moderate - HDFC Securities

Q2 FY21 GDP: Light at the end of the tunnel - YES Securities

Siemens - Q4 FY20 Result Update - YES Securities

Super action in Home Loans - SBIN, ICICIBC, AXSB, HDFC and LICHF gaining share - YES Securities

Polymer price tracker - Dec 1, 2020 - PVC prices continue to tread higher - ICICI Securities

Bajaj Finance - Company Update - Dec 2020 - ICICI Direct

Siemens Ltd - Healthy revival in orders and margins - ICICI Securities

Covid Recovery Pulse - Nov 30, 2020 - Festive positivity continues in auto retails, e-way bill generation improves...

Derivatives Weekly View (November 27): Momentum expected to continue in broader markets with Nifty support at 12800...

Derivatives Strategy - Positional Option - ICICI Direct

Preview on RBI Monetary Policy - December 2020 - Shanti Ekambaram, Group President - Consumer Banking, Kotak Mahindra Bank

10 things you should know about Burger King India Limited

Views of HDFC Securities and Acuité Ratings & Research on Q2FY21 GDP Numbers

Rollover Report for November 2020 - December 2020: Angel Broking

Initiating Coverage on Godrej Properties - The housing factory - HDFC Securities

Burger King IPO - Angel Broking

Rollover Analysis - Record foreign inflows pushes Nifty to 13k - YES Securities

Ceramic tiles industry - Market share gains sustain for top branded players - ICICI Securities

Gas sector - CGD: Competition to hit margins, volumes and lead to derating - ICICI Securities

Cement - Prices resilient in Q3; consensus upgrades to continue - ICICI Securities

Specialty chemicals - Price trend in Sep-20 - ICICI Securities

Timken India - Q2FY21 Company Update - ICICI Direct

Upgrade in target price of IDFC First Bank - Angel Broking

Laurus Labs stake acquisition in Richore Lifesciences - Angel Broking

Shares of Lakshmi Vilas Bank (LVB) suspended from trading - Angel Broking

Initiating Coverage on Sundram Fasteners - Fastening growth - HDFC Securities

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019